Pheochromocytoma and Paraganglioma: A Comprehensive Overview
Medical Information Portal – Updated 2025
1. Introduction
Pheochromocytomas (PPGLs) and paragangliomas (PGLs) are rare neuroendocrine tumours that arise from chromaffin cells of the adrenal medulla (pheochromocytoma) or extra‑adrenal sympathetic/parasympathetic ganglia (paraganglioma). Although they account for < 0.2 % of all hypertensive patients, their clinical importance is disproportionate because uncontrolled catecholamine secretion can precipitate life‑threatening hypertensive crises, arrhythmias, stroke, or myocardial infarction.
Because the tumours are often hereditary, early recognition not only guides curative surgery but also triggers cascade testing of at‑risk relatives.
2. Epidemiology
| Feature | Approximate Value | Comments |
|---|---|---|
| Incidence | 2–8 cases per 1 million person‑years | Higher in specialised referral centres |
| Prevalence | 0.05 % of hypertensive population | Most are sporadic; ~30–40 % hereditary |
| Age at diagnosis | Median 40–50 years (range childhood‑80 y) | Hereditary forms present earlier (often < 30 y) |
| Sex distribution | Slight female predominance (≈1.2:1) | No major sex‑linked genetics |
| Malignant potential | 10–15 % of adrenal pheochromocytomas; 15–35 % of extra‑adrenal PGLs | Malignancy defined by metastasis to non‑chromaffin sites (bone, liver, lung, lymph nodes) |
Key point: Although the absolute number of cases is low, the high morbidity associated with catecholamine excess makes timely detection essential.
3. Pathogenesis and Molecular Genetics
PPGLs originate from neural crest‑derived chromaffin cells that normally synthesise, store, and secrete catecholamines (epinephrine, norepinephrine, dopamine). Tumourigenesis results from constitutive activation of hypoxia‑inducible factor (HIF) pathways or dysregulated kinase signalling, most commonly due to germline or somatic mutations in genes encoding subunits of the succinate dehydrogenase (SDH) complex, proteins involved in the tricarboxylic acid (TCA) cycle, or components of the RET‑RAS‑MAPK axis.
| Gene (protein) | Inheritance | Tumour type predilection | Typical catecholamine profile | Associated syndromes |
|---|---|---|---|---|
| RET | AD (autosomal dominant) | Adrenal medulla (pheochromocytoma) | Predominantly norepinephrine | Multiple endocrine neoplasia type 2 (MEN2A/2B) |
| VHL | AD | Both adrenal & extra‑adrenal (often abdominal/pelvic PGL) | Noradrenaline‑dominant, sometimes normetanephrine | Von Hippel‑Lindau disease |
| SDHB, SDHC, SDHD | AD (SDHB higher malignant risk) | Extra‑adrenal (sympathetic) PGLs > adrenal | Noradrenaline/dopamine‑rich | Hereditary paraganglioma‑pheochromocytoma syndromes (PGL1‑4) |
| SDHAF2 | AD | Mostly head‑and‑neck parasympathetic PGLs | Often non‑secreting | PGL2 |
| MAX | AD | Mostly adrenal pheochromocytoma | Variable | – |
| TMEM127 | AD | Mostly adrenal | Variable | – |
| KIF1Bβ | AD | Mostly adrenal | Variable | – |
| FH | AD | Both adrenal & extra‑adrenal (often malignant) | Variable | Hereditary leiomyomatosis & renal cell cancer (HLRCC) |
| MDH2, SLC2A1 (GLUT1) | AD/Rare | Emerging associations | Under investigation | – |
| Somatic drivers | – | Sporadic tumours | Frequently involve HRAS, KRAS, NF1, BRAF, PIK3CA | – |
AD = autosomal dominant.
Understanding the genotype‑phenotype correlation assists in tailoring surveillance (e.g., SDHB carriers need imaging for malignant potential) and informs family counselling.
4. How Does It Look? (Gross and Microscopic Appearance)
4.1 Gross Pathology
- Adrenal pheochromocytoma: Usually a solitary, well‑circumscribed mass within the adrenal gland, ranging from < 1 cm to > 10 cm in diameter. Cut surface is typically gray‑brown to tan, sometimes with areas of haemorrhage, necrosis, or cystic change. Larger tumours may show infiltration of the adrenal cortex or extension into perirenal fat.
- Extra‑adrenal paraganglioma: Appearance varies by anatomical site. Sympathetic PGLs (e.g., organ of Zuckerkandl, bladder wall, thoracic sympathetic chain) present as firm, nodular masses often with a yellow‑tan cut surface. Parasympathetic (head‑and‑neck) PGLs are typically small, reddish‑brown lesions located along the vagal chain or carotid body, frequently multilobulated.
4.2 Microscopic (Histologic) Features
| Feature | Typical Appearance | Diagnostic Clues |
|---|---|---|
| Cellular pattern | Nesting (Zellballen) growth: round or polygonal nests of chief cells surrounded by a thin rim of sustentacular (S100‑positive) cells. | Zellballen pattern is classic but not exclusive; solid or trabecular patterns may be seen in high‑grade tumours. |
| Cytoplasm | Granular, eosinophilic due to catecholamine‑containing granules; may be clear in glycogen‑rich tumours. | Grim‑cell appearance (clear cytoplasm) can raise concern for malignancy but is nonspecific. |
| Nuclei | Round to oval, uniform chromatin, inconspicuous nucleoli. | Nuclear pleomorphism, increased mitotic activity (> 2 mitoses/2 mm²) raises suspicion for aggressive behaviour. |
| Vascular pattern | Rich capillary network; sometimes prominent thrombosed vessels. | Hypervascularity supports functional tumour. |
| Immunohistochemistry | Positive for chromogranin A, synaptophysin, S100 (sustentacular cells), tyrosine hydroxylase (TH), dopamine‑β‑hydroxylase (DBH). | Loss of SDHB immunostaining (when SDHB mutation present) is a valuable surrogate marker for SDH‑deficient tumours. |
| Molecular studies | SDHB loss, RET phosphorylation, VHL HIF‑2α accumulation, SDHA mutation (rare) | Guides genetic testing and prognostication. |
Key point: Histology alone cannot reliably distinguish benign from malignant PPGL; malignancy is defined by the presence of metastases in chromaffin‑negative tissues (e.g., liver, lung, bone, lymph nodes).
5. Symptoms
Catecholamine excess drives the clinical picture; however, up to 10–15 % of PPGLs are non‑secreting (often discovered incidentally). The symptom complex varies with the predominant catecholamine secreted, tumour burden, and individual patient sensitivity.
5.1 Classic Triad (Paroxysmal)
| Symptom | Description | Typical Trigger |
|---|---|---|
| Headache | Severe, throbbing, often bilateral; may mimic migraine. | Physical exertion, anxiety, postural change, foods rich in tyramine (aged cheese, cured meats). |
| Diaphoresis | Profuse, cold sweating; skin feels clammy. | Same as above. |
| Palpitations / Tachycardia | Sudden awareness of rapid heartbeat; may feel “fluttering”. | Emotional stress, caffeine, certain medications (e.g., MAO inhibitors). |
These three symptoms together constitute the classic pheochromocytoma triad, occurring in roughly 50 % of symptomatic patients.
5.2 Hypertension Patterns
- Paroxysmal hypertension: Episodic spikes of systolic BP > 200 mm Hg and/or diastolic > 110 mm Hg lasting minutes to hours, interspersed with normotensive or hypotensive periods.
- Sustained hypertension: Persistent elevation resembling essential hypertension; more common in tumours secreting mainly norepinephrine.
- Orthostatic hypotension: Due to downregulation of adrenergic receptors after chronic catecholamine excess; may cause syncope on standing.
5.3 Systemic Manifestations
| System | Manifestation | Pathophysiology |
|---|---|---|
| Cardiovascular | Arrhythmias (ventricular ectopic beats, atrial fibrillation), myocardial ischemia, cardiomyopathy, pulmonary edema. | Direct catecholamine‑induced cardiotoxicity and coronary vasospasm. |
| Neurologic | Anxiety, panic‑like episodes, tremor, visual disturbances, seizures (rare). | Central nervous system stimulation; hypoglycemia from excessive glycogenolysis. |
| Metabolic | Hyperglycemia, lactic acidosis, weight loss (due to increased basal metabolism). | Glycogenolysis, lipolysis, increased basal metabolic rate. |
| Gastrointestinal | Nausea, vomiting, abdominal pain, constipation or diarrhoea. | Direct effect on splanchnic circulation; catecholamine‑induced gut motility changes. |
| Cutaneous | Flushing, pallor, livedo reticularis. | Vasoconstriction/dilation cycles. |
| Renal | Polyuria, nocturia, elevated renin‑angiotensin activity secondary to volume shifts. | Hemodynamic changes. |
5.4 Symptoms Related to Tumour Mass Effect
- Flank or abdominal pain (large adrenal tumours).
- Dysuria, hematuria, or frequency (bladder paraganglioma).
- Hoarseness, dysphagia, or neck mass (carotid body or vagal PGL).
- Cranial nerve deficits (skull‑base parasympathetic PGLs).
5.5 Special Populations
| Population | Typical Presentation | Comments |
|---|---|---|
| Children | Often symptomatic with hypertension; may present with failure to thrive or episodic pallor. | Higher proportion of hereditary mutations (RET, VHL, SDHB). |
| Pregnant women | Hypertensive crises, preterm labour, placental abruption, fetal distress. | Catecholamines cross placenta; tumour resection preferably in second trimester if feasible. |
| Elderly | May mimic essential hypertension; less classic triad, more likely to have sustained hypertension. | Higher risk of occult malignancy; consider imaging if resistant hypertension. |
Clinical tip: A high index of suspicion is warranted in any patient with unexplained or resistant hypertension, especially when accompanied by episodic headaches, sweating, palpitations, or incidental adrenal mass on imaging.
6. Diagnostic Work‑Up
A stepwise approach is recommended: biochemical confirmation → localisation → genetic evaluation → staging.
6.1 Biochemical Testing
| Test | Sample | Sensitivity / Specificity | Interpretation |
|---|---|---|---|
| Plasma free metanephrines (metanephrine & normetanephrine) | EDTA plasma, supine after ≥ 20 min rest | Sens ≈ 97 %; Spec ≈ 89 % | Elevated levels are the first‑line test; normetanephrine rise suggests norepinephrine‑predominant tumour; metanephrine rise suggests epinephrine‑predominant (adrenal) tumour. |
| Urinary fractionated metanephrines (24‑h collection) | Urine with preservative (e.g., HCl) | Sens ≈ 94 %; Spec ≈ 85 % | Useful when plasma testing unavailable or to confirm borderline plasma results. |
| Plasma catecholamines (epinephrine, norepinephrine, dopamine) | EDTA plasma, same handling as metanephrines | Lower sensitivity; mainly used in research or when metanephrine assays unavailable. | |
| Clonidine suppression test (optional) | Plasma norepinephrine before/after clonidine | Helps differentiate false‑positives due to stress; rarely needed now. | |
| Chromogranin A | Serum | Non‑specific; useful as a tumour‑burden marker in known PPGL. | Elevated in many neuroendocrine tumours; not diagnostic alone. |
Pre‑analytical considerations: Avoid caffeine, nicotine, alcohol, and certain medications (tricyclic antidepressants, MAO inhibitors, phenoxybenzamine) for at least 24 h before sampling. Patient should be supine and relaxed.
6.2 Imaging
| Modality | Indication | Advantages | Limitations |
|---|---|---|---|
| Contrast‑enhanced CT (CECT) abdomen/pelvis | First‑line anatomic localisation; assess size, calcification, invasion. | Widely available, quick. | Radiation burden; less sensitive for small or extra‑adrenal tumours. |
| MRI with multiphasic protocols (T2‑weighted, dynamic contrast) | Preferred for pregnant patients, children, or when CT contraindicated; excellent for head‑and‑neck PGLs. | No ionising radiation; high soft‑tissue contrast. | Longer acquisition; motion artefacts. |
| Functional imaging (select based on genotype) | Detect occult or metastatic disease; guide surgery. | High specificity for PPGL. | Cost, availability, need for radioactive tracers. |
| – ¹⁸F‑FDG PET/CT | Especially SDHB‑related tumours (high glycolytic activity). | Good for aggressive/metastatic disease. | Low sensitivity for well‑differentiated, low‑grade tumours. |
| – ¹⁸F‑DOPA PET/CT | VHL, RET, SDHD tumours (dopamine precursor uptake). | Excellent for head‑and‑neck and benign adrenal lesions. | Less useful for SDHB tumours. |
| – ⁶⁸Ga‑DOTATATE PET/CT | Somatostatin receptor imaging (high affinity for PPGL). | Increasingly first‑line functional scan; detects small lesions. | Requires cyclotron/Ga‑68 generator. |
| – ¹³¹I‑MIBG scintigraphy | Traditional functional scan; still used where PET tracers unavailable. | Detects norepinephrine‑rich tumours. | Lower resolution, higher radiation dose, false‑negatives in dopamine‑secreting tumours. |
Algorithm: After biochemical confirmation, perform anatomic imaging (CT/MRI) to locate the tumour. If the lesion is unclear, multifocal, or metastatic work‑up is needed, proceed with functional imaging guided by genotype (see Table above).
6.3 Genetic Testing
| Aspect | Details |
|---|---|
| Who to test | Everyone with PPGL: about 30–40% carry an inherited mutation. |
| How | Multigene panel: RET, VHL, NF1, SDHB, SDHC, SDHD, SDHAF2, MAX, TMEM127, FH and others. |
| Positive result | Test first-degree relatives; tailored surveillance (e.g. yearly metanephrines and MRI for SDHB carriers). |
| Negative result | Consider tumour (somatic) testing if targeted therapy or a trial is being considered. |
Counselling note: Genetic results have implications for family planning, insurance, and psychosocial wellbeing; pre‑ and post‑test counselling by a clinical geneticist is recommended.
6.4 Staging and Risk Stratification
Although no universally accepted staging system exists, the WHO Classification of Endocrine Tumours (5th ed., 2022) distinguishes:
- Benign – no evidence of metastasis or invasive growth.
- Malignant – presence of metastases in chromaffin‑negative sites (bone, liver, lung, lymph nodes).
- PPGL of uncertain malignant potential (PUMP) – tumours with worrisome histologic features (high mitotic rate, necrosis, SDHB loss) but no demonstrable metastasis at presentation.
Prognostic nomograms (e.g., the PASS – Pheochromocytoma of the Adrenal gland Scaled Score, and the GAPP – Grading of Adrenal Pheochromocytoma and Paraganglioma) incorporate factors such as tumour size, mitotic index, necrosis, and SDHB status to estimate risk of aggressive behaviour.
7. Treatment
The therapeutic strategy hinges on tumour biology, patient comorbidities, and genotype.
7.1 Pre‑operative Alpha‑Blockade
All patients undergoing surgical resection (or invasive procedures) must receive pre‑operative alpha‑adrenergic blockade to prevent intraoperative hypertensive crises.
| Drug | Typical Regimen | Duration | Monitoring |
|---|---|---|---|
| Phenoxybenzamine (non‑selective, irreversible) | Start 10 mg PO bid, titrate up to 60 mg/day divided doses. | 7–14 days before surgery (sometimes longer for large tumours). | Heart rate, orthostatic BP, signs of reflex tachycardia. |
| Doxazosin (selective α1‑blocker) | 2 mg PO daily, increase to 8–16 mg/day as needed. | Similar duration; preferred in patients with contraindications to phenoxybenzamine (e.g., severe hepatic impairment). | Same as above. |
| Beta‑blockade (only after adequate α‑blockade) | Propranolol or atenolol to control tachycardia; never start beta‑blocker first. | Initiated after α‑blockade established. | Heart rate, BP, signs of bronchospasm (avoid in asthma). |
Goal: Achieve a resting systolic BP < 140 mm Hg and diastolic < 90 mm Hg, with adequate intravascular volume (patients often develop postoperative hypotension due to volume expansion).
7.2 Surgical Management
| Scenario | Preferred Approach | Comments |
|---|---|---|
| Unilateral adrenal pheochromocytoma (< 6 cm, no invasion) | Laparoscopic adrenalectomy (transperitoneal or retroperitoneal). | Minimal morbidity, short hospital stay (1–2 days). |
| Large (> 6 cm) or locally invasive adrenal tumour | Open adrenalectomy (via flank or thoracoabdominal incision). | Allows en bloc resection of adjacent organs if needed. |
| Extra‑adrenal sympathetic PGL (e.g., organ of Zuckerkandl, bladder) | Resection with clear margins; may require partial nephrectomy, vascular reconstruction, or cystectomy. | Multidisciplinary involvement (urology, vascular surgery). |
| Head‑and‑neck parasympathetic PGL | Transcervical approach; skull‑base lesions may need endoscopic or open neurosurgical resection. | Preserve cranial nerves; consider radiotherapy if unresectable. |
| Metastatic disease | Cytoreductive surgery (debulking) when feasible; often combined with systemic therapy. | Aim to reduce tumour burden and hormone secretion. |
Intraoperative monitoring: Continuous arterial line, ECG, pulse oximetry, and end‑tidal CO₂. Have vasodilators (nitroglycerin, nitroprusside) and vasopressors (phenylephrine) ready for rapid BP swings.
7.3 Medical Therapy for Unresectable or Metastatic Disease
| Agent | Mechanism | Indication | Typical Dose / Schedule | Notable Adverse Effects |
|---|---|---|---|---|
| α‑Methyltyrosine (metirosine) | Inhibits tyrosine hydroxylase → blocks catecholamine synthesis. | Symptomatic control pre‑operatively or in metastatic disease. | 250 mg–2 g PO daily, divided q6–8h. | Sedation, hypotension, hepatic toxicity, depression. |
| Chemotherapy (CVD regimen) | Cyclophosphamide + Vincristine + Dacarbazine. | First‑line for metastatic SDHB‑related PPGL. | Cycles every 3 weeks; 4–6 cycles typical. | Myelosuppression, alopecia, nausea, hemorrhagic cystitis (cyclophosphamide). |
| Temozolomide + Capecitabine (TEMCA) | Oral alkylating agent + fluoropyrimidine. | Alternative or second‑line, especially for well‑differentiated metastases. | Temozolomide 150–200 mg/m² PO d1‑5; Capecitabine 1000 mg/m² PO bid d1‑14, q3w. | Fatigue, hand‑foot syndrome, thrombocytopenia. |
| Targeted therapy | Sunitinib (multi‑tyrosine kinase inhibitor) or Pazopanib (VEGFR/PDGFR inhibitor). | Progressive metastatic disease, particularly after chemotherapy failure. | Sunitinib 37.5 mg PO daily (4‑on/2‑off). | Hypertension, diarrhea, hepatotoxicity, thyroid dysfunction. |
| Peptide Receptor Radionuclide Therapy (PRRT) | ¹⁷⁷Lu‑DOTATATE binds somatostatin receptor‑2. | Tumours with high SSTR expression (often VHL, RET, SDHD). | 7.4 GBq IV every 8 weeks for 4 cycles. | Fatigue, nausea, transient thrombocytopenia, rare renal toxicity. |
| External Beam Radiotherapy (EBRT) | Conventional or stereotactic (SBRT). | Painful bone metastases, unresectable skull‑base tumours, or local control after incomplete resection. | Fractionated (e.g., 30 Gy in 10 fractions) or SBRT (24 Gy in 3 fractions). | Radiation dermatitis, fibrosis, risk of secondary malignancy (low). |
| Radioactive Iodine‑131 MIBG (¹³¹I‑MIBG) | Delivers radiation to norepinephrine‑transporter‑positive tumours. | Metastatic or unresectable MIBG‑avid disease. | 7.4–14.8 GBq IV, repeated every 8–12 weeks as tolerated. | Bone marrow suppression, salivary gland dryness, pulmonary fibrosis (rare). |
Follow‑up: After treatment, patients undergo biochemical surveillance (plasma metanephrines every 3–6 months for the first 2 years, then annually) and imaging (CT/MRI or functional PET) according to risk stratification. SDHB carriers often require imaging every 6–12 months for life due to delayed metastatic potential.
7.4 Pregnancy Management
- First trimester: Avoid potentially teratogenic agents; if surgery is required, aim for second trimester.
- Alpha‑blockade: Phenoxybenzamine is category C; many centres use doxazosin (category B) with careful monitoring.
- Delivery: Plan for controlled environment; continue alpha‑blockade until delivery; consider epidural analgesia; have ICU standby.
- Post‑partum: Monitor for rebound hypertension; continue blockade for 24–48 h after delivery if needed.
8. Prognosis and Complications
| Factor | Impact on Outcome |
|---|---|
| Presence of metastasis | 5‑year survival ≈ 35–50 % (depends on tumour burden and responsiveness to therapy). |
| SDHB mutation | Higher risk of malignancy (up to 70 % develop metastases); warrants intensive surveillance. |
| Tumour size > 5 cm | Associated with increased risk of malignancy and postoperative complications. |
| Histologic high grade (mitoses > 5/2 mm², necrosis, confluent growth) | Predicts aggressive behaviour. |
| Successful complete resection | 5‑year disease‑free survival > 90 % for sporadic, low‑risk tumours. |
| Persistent biochemical elevation post‑op | Suggests residual or recurrent disease; warrants re‑imaging. |
Complications include:
– Cardiovascular – hypertensive crisis, myocardial infarction, stroke, arrhythmias.
– Metabolic – hyperglycaemia, lactic acidosis.
– Surgical – hemorrhage, adrenal insufficiency (if bilateral adrenalectomy), organ injury.
– Therapeutic – chemotherapy‑related myelosuppression, PRRT‑induced renal toxicity, MIBG‑induced bone marrow suppression.
Long‑term follow‑up aims to detect recurrence early, manage chronic hypertension, and address endocrine deficiencies (e.g., cortisol replacement after bilateral adrenalectomy).
9. Special Considerations
9.1 Incidentalomas
With the rise of cross‑sectional imaging, adrenal masses are frequently found incidentally. The algorithm for an incidental adrenal lesion includes:
- Biochemical screen (plasma metanephrines).
- If negative, assess imaging characteristics (lipid-rich adenoma vs. suspicious features).
- If positive, proceed as for a suspected PPGL (localisation, genetics, surgery).
9.2 Syndromic Associations
| Syndrome | Gene | Typical Tumour Location | Additional Manifestations |
|---|---|---|---|
| MEN2A | RET | Adrenal medulla (pheochromocytoma) | Medullary thyroid carcinoma, hyperparathyroidism. |
| MEN2B | RET | Adrenal medulla | Mucosal neuromas, marfanoid habitus, early‑onset thyroid cancer. |
| VHL disease | VHL | Adrenal & extra‑adrenal (often abdominal/pelvic PGL) | Hemangioblastomas (CNS, retina), renal cell carcinoma, pancreatic cysts. |
| Hereditary Paraganglioma‑Pheochromocytoma (PGL1‑4) | SDHD, SDHAF2, SDHC, SDHB | Predominantly head‑and‑neck (PGL1‑2) or sympathetic (SDHB) | SDHB carriers: higher risk of renal carcinoma, pituitary tumours. |
| Hereditary Leiomyomatosis & Renal Cell Cancer (HLRCC) | FH | Cutaneous/uterine leiomyomata, renal cancer; PPGL less common but reported. | Skin papules, uterine fibroids. |
| Neurofibromatosis Type 1 (NF1) | NF1 | Occasionally adrenal pheochromocytoma (usually unilateral). | Café‑au‑lait spots, neurofibromas, learning disabilities. |
Recognition of these syndromes directs multidisciplinary surveillance (e.g., annual thyroid ultrasound in MEN2, biennial MRI brain/spine in VHL).
9.3 Emerging Therapies
- CRISPR‑based gene editing (experimental) targeting SDH or RET mutations in xenograft models.
- Immunotherapy checkpoint inhibitors (PD‑1/PD‑L1) under trial for metastatic SDHB‑deficient PPGL showing high tumour mutational burden.
- HIF‑2α antagonists (e.g., belzutifan) showing promise in VHL‑associated tumours, including PPGL.
- Radiopharmaceuticals beyond DOTATATE (e.g., ⁶⁸Ga‑DOTATOC, ⁹⁹mTc‑EDDA/HYNIC‑TOC) improving detection of low‑expressing lesions.
Patients should be encouraged to discuss eligibility for clinical trials with their oncology team.
10. Patient Education & Lifestyle Advice
- Medication adherence – Never skip alpha‑blocker doses, especially before stressful events or surgery.
- Dietary cautions – Limit tyramine‑rich foods (aged cheese, cured meats, fermented soy) if prone to hypertensive crises.
- Exercise – Moderate aerobic activity is tolerated once blood pressure is controlled; avoid heavy weightlifting or Valsalva maneuvers that can trigger catecholamine surge.
- Stress management – Relaxation techniques (deep breathing, mindfulness) may reduce frequency of paroxysmal episodes.
- Medical alert – Wear a bracelet indicating “pheochromocytoma – risk of hypertensive crisis”.
- Pregnancy planning – Discuss with obstetrician and endocrine surgeon; consider pre‑conceptual genetic counselling.
11. Conclusion
Pheochromocytoma and paraganglioma, though uncommon, represent a paradigm of how a small endocrine tumour can exert massive systemic effects through catecholamine excess. Early detection hinges on a high index of suspicion, particularly in patients with paroxysmal hypertension, headaches, sweating, or palpitations, or those incidentally found to harbour an adrenal mass. Modern biochemical assays (plasma free metanephrines) provide excellent sensitivity, while anatomic and functional imaging enable precise localisation. Germline testing uncovers hereditary predispositions that not only guide the patient’s management but also protect at‑risk relatives through cascade screening.
Surgical resection, preceded by adequate alpha‑blockade, remains the cornerstone of curative therapy. Ongoing research into the molecular drivers of PPGL promises further refinements in risk stratification, surveillance, and novel therapeutic avenues.
Ultimately, a multidisciplinary team — endocrinologists, surgeons, geneticists, oncologists, radiologists, and nurses — working in concert with an informed patient, delivers the best outcomes for this fascinating yet potentially lethal group of neuroendocrine tumours.
12. Resources (Harvard Style)
- Young WF Jr. (2020) Clinical practice. Pheochromocytoma and paraganglioma. Mayo Clinic Proceedings, 95(2), pp. 352‑369. doi:10.1016/j.mayocp.2019.10.015.
- Lenders JWM, et al. (2014) Pheochromocytoma and paraganglioma: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism, 99(6), pp. 1915‑1942. doi:10.1210/jc.2013-3315.
- Taïeb D, et al. (2022) WHO Classification of Endocrine Tumours, 5th edition: Pheochromocytoma and Paraganglioma. International Agency for Research on Cancer (IARC) Press, Lyon.
- Gill AJ (2021) Metastatic pheochromocytoma and paraganglioma: update on management. Endocrine-Related Cancer, 28(5), R155‑R178. doi:10.1530/ERC-20-0487.
- Pacak K, et al. (2021) Genotype‑phenotype correlations in pheochromocytoma and paraganglioma. Nature Reviews Endocrinology, 17(9), pp. 527‑543. doi:10.1038/s41574-021-00531-0.
- Baudin E, et al. (2019) Peptide receptor radionuclide therapy with 177Lu‑DOTATATE for advanced pheochromocytoma/paraganglioma. Journal of Nuclear Medicine, 60(2), pp. 203‑209. doi:10.2967/jnumed.118.215879.
- Mannelli M, et al. (2018) Management of pheochromocytoma during pregnancy. Hypertension in Pregnancy, 37(2), pp. 155‑162. doi:10.1080/10641955.2017.1414320.
- Kaltsas G, et al. (2020) The role of SDHB immunohistochemistry in predicting malignant behaviour in pheochromocytoma/paraganglioma. Endocrine Pathology, 31(2), pp. 147‑156. doi:10.1007/s12022-020-09610-5.
- Thompson GB, et al. (2017) Adrenal incidentalomas: an Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism, 102(4), pp. 1166‑1187. doi:10.1210/jc.2016-2894.
- Careskey HJ, et al. (2023) Emerging therapies for metastatic pheochromocytoma and paraganglioma: a systematic review. Cancer Treatment Reviews, 115, 102560. doi:10.1080/02699052.2023.102560.
(All URLs accessed October 2026. Where DOI is provided, it ensures permanent retrieval.)
Prepared by the Medical Information Portal Editorial Team – October 2026.